全文获取类型
收费全文 | 49062篇 |
免费 | 4324篇 |
国内免费 | 1660篇 |
专业分类
耳鼻咽喉 | 436篇 |
儿科学 | 1029篇 |
妇产科学 | 755篇 |
基础医学 | 3534篇 |
口腔科学 | 1689篇 |
临床医学 | 6217篇 |
内科学 | 11027篇 |
皮肤病学 | 1242篇 |
神经病学 | 2052篇 |
特种医学 | 2059篇 |
外科学 | 3815篇 |
综合类 | 7499篇 |
现状与发展 | 13篇 |
一般理论 | 4篇 |
预防医学 | 6221篇 |
眼科学 | 934篇 |
药学 | 3893篇 |
32篇 | |
中国医学 | 1992篇 |
肿瘤学 | 603篇 |
出版年
2024年 | 52篇 |
2023年 | 1116篇 |
2022年 | 1585篇 |
2021年 | 2633篇 |
2020年 | 2643篇 |
2019年 | 2201篇 |
2018年 | 2012篇 |
2017年 | 1695篇 |
2016年 | 1888篇 |
2015年 | 1751篇 |
2014年 | 3309篇 |
2013年 | 3961篇 |
2012年 | 2857篇 |
2011年 | 3126篇 |
2010年 | 2528篇 |
2009年 | 2370篇 |
2008年 | 2328篇 |
2007年 | 2335篇 |
2006年 | 1971篇 |
2005年 | 1800篇 |
2004年 | 1455篇 |
2003年 | 1291篇 |
2002年 | 1074篇 |
2001年 | 1045篇 |
2000年 | 816篇 |
1999年 | 621篇 |
1998年 | 554篇 |
1997年 | 480篇 |
1996年 | 343篇 |
1995年 | 418篇 |
1994年 | 355篇 |
1993年 | 253篇 |
1992年 | 294篇 |
1991年 | 264篇 |
1990年 | 197篇 |
1989年 | 207篇 |
1988年 | 192篇 |
1987年 | 174篇 |
1986年 | 152篇 |
1985年 | 143篇 |
1984年 | 108篇 |
1983年 | 71篇 |
1982年 | 67篇 |
1981年 | 35篇 |
1980年 | 47篇 |
1979年 | 51篇 |
1978年 | 34篇 |
1977年 | 41篇 |
1976年 | 28篇 |
1975年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
《Journal of Cardiovascular Computed Tomography》2022,16(6):483-490
BackgroundInflammation surrounding the coronary arteries can be non-invasively assessed using pericoronary adipose tissue attenuation (PCAT). While PCAT holds promise for further risk stratification of patients with low coronary artery disease (CAD) prevalence, its value in higher risk populations remains unknown.MethodsCORE320 enrolled patients referred for invasive coronary angiography with known or suspected CAD. Coronary computed tomography angiography (CCTA) images were collected for 381 patients for whom clinical outcomes were assessed 5 years after enrollment. Using semi-automated image analysis software, PCAT was obtained and normalized for the right coronary (RCA), left anterior descending (LAD), and left circumflex arteries (LCx). The association between PCAT and major adverse cardiovascular events (MACE) during follow up was assessed using Cox regression models.ResultsThirty-seven patients were excluded due to technical failure. For the remaining 344 patients, median age was 62 (interquartile range, 55–68) with 59% having ≥1 coronary artery stenosis of ≥50% by quantitative coronary angiography. Mean attenuation values for PCAT in RCA, LAD, and LCx were ?74.9, ?74.2, and ?71.2, respectively. Hazard ratios and 95% confidence intervals (CI) for normalized PCAT in the RCA, LAD, and LCx for MACE were 0.96 (CI: 0.75–1.22, p ?= ?0.71), 1.31 (95% CI: 0.96–1.78, p ?= ?0.09), and 0.98 (95% CI: 0.78–1.22, p ?= ?0.84), respectively. For death, stroke, or myocardial infarction only, hazard ratios were 0.68 (0.44–1.07), 0.85 (0.56–1.29), and 0.57 (0.41–0.80), respectively.ConclusionsIn patients referred for invasive coronary angiography with suspected CAD, PCAT did not predict MACE during long term follow up. Further studies are needed to understand the relationship of PCAT with CAD risk. 相似文献
4.
《Indian journal of medical microbiology》2022,40(4):480-484
BackgroundInvasive Fungal Diseases (IFD), account for high morbidity and mortality in immunocompromised and seriously ill patients worldwide. Early, faster and accurate diagnosis with timely and appropriate patient management is critical for improved patient outcome and antifungal stewardship. Clinical/radiological presentations in IFD are non-specific and microscopy/culture based tests have low sensitivity and long turnaround time. Biomarkers have clinical utility for diagnosing IFD but their interpretation is not straight forward.ObjectivesThis review discusses the salient characteristics, clinical usefulness and limitations of common biomarkers such as Galactomannan (GM), 1–3, β D glucan (βDG), mannan, anti-mannan antibody (Mn/antiMn), Cryptococcal antigen test (CrAg), Nucleic Acid Amplification (NAA) tests and next generation sequencing for diagnosing IFD.ContentsFungal biomarkers are useful adjuncts as screening and diagnostic tools for IFD and are much more suited for ‘ruling out’ rather than ‘ruling in’ disease. GM, NAA tests are promising biomarkers for screening of invasive Aspergillosis in high risk asymptomatic patients who are not on antifungal therapy and for diagnosis of breakthrough infections in symptomatic patients. 1–3, β D glucan has limitations both as a ‘rule in’ and ‘rule out’ test and is useful in only specific clinical settings. Two consecutive positive 1-3-βDG tests or combined positivity with GM increases its specificity. Mn/antiMn, T2Candida nano diagnostic panel are promising candidates for diagnosing invasive candidiasis. Combining two or more biomarkers improves the sensitivity for prompt initiation of antifungal therapy and the negative predictive value for suspension of empirical treatment.Serum CrAg test is a good ‘rule in’ rather than a ‘rule out’ test in immunocompetent patients but has good diagnostic accuracy in immunocompromised patients. Detection of single nucleotide polymorphisms by next generation sequencing is useful for fungal characterization and identification of host determinants responsible for increased susceptibility to fungal infections but is still in experimental stages. 相似文献
5.
6.
7.
《Arab Journal Of Gastroenterology》2022,23(1):58-60
A liver abscess is identified as a rare extraintestinal manifestation of Crohn’s disease, with an incidence of approximately 150 in 100,000 patients with this condition. In many of these patients, infectious causes are identified, and the patient’s condition is often noted to improve with antibiotics. An aseptic abscess (AA) is an increasingly recognized entity, especially in patients with inflammatory bowel disease, where repetitive evaluations to identify the infectious cause are futile. The average age of diagnosis for an AA is 29 years. The most common site is the spleen, followed by the lymph nodes and then the liver. In this study, we present a unique case of extensive aseptic liver abscesses extending into the pleural cavity in a young patient with Crohn’s disease. 相似文献
9.
10.
《Drug discovery today》2022,27(6):1724-1732
The enactment of orphan drug-specific legislation pioneered by the USA was subsequently followed by many regions, including the European Union (EU), Australia, Japan, and Taiwan. Here, we discuss the associated regulations established and their impacts in the aforementioned regions, which are among the first with frameworks specific for orphan drugs. Varied scopes of rare diseases or orphan drugs, diverse incentives, and heterogeneous types of reimbursement systems imply the prioritization of the agencies concerned. The numbers of designated and approved drugs reflect the impact of the regulatory and reimbursement frameworks. A comparison of the frameworks and their impact in the respective regions could provide valuable information for developing and improving related frameworks for countries worldwide. 相似文献